Pure Financial Advisors LLC Grows Position in Abbott Laboratories $ABT

Pure Financial Advisors LLC boosted its stake in shares of Abbott Laboratories (NYSE:ABT) by 162.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 23,306 shares of the healthcare product maker’s stock after acquiring an additional 14,423 shares during the period. Pure Financial Advisors LLC’s holdings in Abbott Laboratories were worth $3,170,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in ABT. Woodward Diversified Capital LLC grew its position in shares of Abbott Laboratories by 30.5% during the second quarter. Woodward Diversified Capital LLC now owns 6,056 shares of the healthcare product maker’s stock valued at $824,000 after purchasing an additional 1,417 shares in the last quarter. Community Financial Services Group LLC boosted its stake in Abbott Laboratories by 874.7% during the second quarter. Community Financial Services Group LLC now owns 45,110 shares of the healthcare product maker’s stock valued at $6,135,000 after buying an additional 40,482 shares during the last quarter. Madrona Financial Services LLC grew its holdings in Abbott Laboratories by 9.7% during the 2nd quarter. Madrona Financial Services LLC now owns 1,726 shares of the healthcare product maker’s stock valued at $235,000 after buying an additional 152 shares in the last quarter. SOA Wealth Advisors LLC. increased its stake in Abbott Laboratories by 142.5% in the 2nd quarter. SOA Wealth Advisors LLC. now owns 1,113 shares of the healthcare product maker’s stock worth $151,000 after acquiring an additional 654 shares during the last quarter. Finally, Parkwoods Wealth Partners LLC purchased a new stake in shares of Abbott Laboratories during the 2nd quarter worth approximately $208,000. Institutional investors own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ABT. Jefferies Financial Group raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and raised their target price for the company from $143.00 to $145.00 in a report on Friday, July 18th. Mizuho boosted their target price on shares of Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a report on Wednesday, July 16th. Morgan Stanley increased their price target on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. William Blair raised Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, July 17th. Finally, Royal Bank Of Canada upped their price objective on Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a research report on Tuesday, July 15th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $145.39.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $133.53 on Thursday. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23. The company has a market capitalization of $232.39 billion, a PE ratio of 16.73, a price-to-earnings-growth ratio of 2.54 and a beta of 0.69. The stock’s fifty day moving average is $131.63 and its two-hundred day moving average is $131.24. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.26. The firm had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business’s revenue was up 7.4% on a year-over-year basis. During the same period in the previous year, the firm earned $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be paid a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 annualized dividend and a yield of 1.8%. Abbott Laboratories’s dividend payout ratio is 29.57%.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the firm’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at $6,862,453.65. This trade represents a 9.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.46% of the stock is owned by insiders.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.